First‑in‑class non‑GLP‑1 peptide advances metabolic therapy
A first‑in‑class non‑GLP‑1 peptide—AT7687, a GIPR antagonist—has entered public awareness, marking a mechanistic departure within metabolic peptide therapeutics.
Key Takeaways
- AT7687 peptide is the first GIPR-targeted, non-GLP-1 peptide to enter clinical testing.
- Phase 1 data show AT7687 peptide is well tolerated and suitable for once-weekly dosing.
- In non-human primates, combining AT7687 peptide with cagrilintide improved weight loss and insulin sensitivity.
What is AT7687 peptide and why does it matter?
AT7687 peptide blocks the glucose-dependent insulinotropic polypeptide receptor (GIPR), a validated but under-explored pathway in metabolic control distinct from GLP-1. Antag Therapeutics reported that Phase 1 results showed AT7687 peptide was well tolerated and suitable for once-weekly subcutaneous injection in people living with obesity, with no notable gastrointestinal tolerability signals(antagtx.com).
How did AT7687 peptide perform in preclinical models?
Antag shared preclinical data in obese, insulin-resistant non-human primates fed a high-fat diet. Animals treated with AT7687 peptide plus the amylin/calcitonin receptor agonist cagrilintide showed additional weight loss and marked improvements in insulin sensitivity and body composition(antagtx.com).
What sets AT7687 peptide apart from GLP-1 therapies?
AT7687 peptide targets GIPR rather than stimulating GLP-1 receptor. GLP-1-based peptides, including agonists and dual agonists, act via incretin pathways. AT7687 peptide works through a different mechanism. Combining it with amylin-based agents like cagrilintide differs from multi-agonist GLP-1 compounds such as tirzepatide or GLP-1/amylin co-agonists, which rely on incretin activation rather than GIP suppression(ncbi.nlm.nih.gov).
FAQ
What is AT7687 peptide?
AT7687 peptide is a first-in-class peptide antagonist of the GIP receptor (GIPR), designed to address obesity and metabolic dysfunction via a non-GLP-1 mechanism.
How does AT7687 peptide differ from GLP-1 therapies?
GLP-1 therapies activate incretin receptors to reduce appetite. AT7687 peptide blocks GIPR, aiming to reduce fat storage and improve insulin sensitivity through a distinct metabolic pathway.
Has AT7687 peptide been tested in humans?
Yes. Phase 1 human data show AT7687 peptide was well tolerated, suitable for once-weekly dosing, without gastrointestinal adverse signals(antagtx.com).
What preclinical evidence supports AT7687 peptide’s potential?
In non-human primate models of obesity, AT7687 peptide combined with cagrilintide drove additional weight loss and improved insulin sensitivity and body composition(antagtx.com).
Could AT7687 peptide become a therapy option soon?
AT7687 peptide’s Phase 2a trial is expected to begin mid-2026, paving the way for further clinical evaluation(antagtx.com).
Note: This article is for general information and is not medical advice. Talk to a licensed clinician before using any peptide product.